Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
about
Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory ActivitySafety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Fungal Infections and New Biologic Therapies.A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
P2860
Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
@en
type
label
Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
@en
prefLabel
Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
@en
P2093
P2860
P356
P1433
P1476
Vedolizumab for the treatment of moderately to severely active ulcerative colitis
@en
P2093
Barrett G Levesque
Brian G Feagan
Parambir S Dulai
Reena Khanna
William J Sandborn
P2860
P304
P356
10.1002/PHAR.1561
P407
P577
2015-04-01T00:00:00Z